Abstract
It is a current idea that carcinogenesis as well as tumor progression are dynamic processes, which involve inherited as well as somatic mutations and include a continuing adaptation to different microenvironmental conditions. There is, in fact, rising evidence that tumor cells are under a persistent stress and that autocrine as well as microenvironment- derived survival factors play a substantial role for the final outcome of the tumor development as well as for response to the anti-tumor therapy. We will review current achievements on the molecular biology of the microenvironment- derived survival signaling and therapeutical approaches, which are presently under clinical development. By the use of plasma cell disorders as an outstanding clinical model, we will discuss the development of novel in vivo preclinical models which recapitulate the human bone marrow milieu. Finally, we will discuss several topics which appear to be relevant for a successful clinical translation of preclinical research in this specific field.
Keywords: Tumor microenvironment, survival pathways, in vivo animal models, in vivo preclinical models, SCID-hu, multiple myeloma, Waldenstrom's macroglobulinemia
Current Pharmaceutical Design
Title: Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Volume: 13 Issue: 5
Author(s): Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Teresa Fulciniti, Maria Teresa Di Martino and Salvatore Venuta
Affiliation:
Keywords: Tumor microenvironment, survival pathways, in vivo animal models, in vivo preclinical models, SCID-hu, multiple myeloma, Waldenstrom's macroglobulinemia
Abstract: It is a current idea that carcinogenesis as well as tumor progression are dynamic processes, which involve inherited as well as somatic mutations and include a continuing adaptation to different microenvironmental conditions. There is, in fact, rising evidence that tumor cells are under a persistent stress and that autocrine as well as microenvironment- derived survival factors play a substantial role for the final outcome of the tumor development as well as for response to the anti-tumor therapy. We will review current achievements on the molecular biology of the microenvironment- derived survival signaling and therapeutical approaches, which are presently under clinical development. By the use of plasma cell disorders as an outstanding clinical model, we will discuss the development of novel in vivo preclinical models which recapitulate the human bone marrow milieu. Finally, we will discuss several topics which appear to be relevant for a successful clinical translation of preclinical research in this specific field.
Export Options
About this article
Cite this article as:
Tassone Pierfrancesco, Tagliaferri Pierosandro, Teresa Fulciniti Maria, Teresa Di Martino Maria and Venuta Salvatore, Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues, Current Pharmaceutical Design 2007; 13 (5) . https://dx.doi.org/10.2174/138161207780162872
DOI https://dx.doi.org/10.2174/138161207780162872 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Current Medicinal Chemistry Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Mind-Body Therapies and Osteoarthritis of the Knee
Current Rheumatology Reviews Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Hyaluronan and Hyaluronan Synthases: Potential Therapeutic Targets in Cancer
Current Drug Targets - Cardiovascular & Hematological Disorders Bone Effects of Glitazones and Other Anti-Diabetic Drugs
Current Drug Safety Spherical Self-Organizing Map Detects MYBL 1 As Candidate Gene for Triple-Negative Breast Cancer
Neuroscience and Biomedical Engineering (Discontinued) Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats
The Natural Products Journal Thioredoxin Reductase and its Inhibitors
Current Protein & Peptide Science Pattern of Care for Skin Cancers - Canada and France
Current Cancer Therapy Reviews Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer
Current Pharmaceutical Biotechnology Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets Therapeutic Proteins and Nanotechnology: Immune Response and Stealth Bioengineered Constructs
Current Drug Metabolism Radiopharmaceutical Chemistry with Iodine-124: A Non-Standard Radiohalogen for Positron Emission Tomography
Medicinal Chemistry Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued)